Targeting host cell factors involved in HIV-1 replication holds promise for HIV-1 inhibition, as no resistance is expected. An emerging factor of interest is p21, which controls cell cycle progression and which levels were increased in HIV-1 elite controllers. A 25-hydroxycholesterol (25HC) is a soluble antiviral factor, which is formed by CH25H from cholesterol and blocks HIV-1 fusion. Administration of 25HC to humanized mice suppresses HIV-1 replication and reverses T cell depletion. We previously showed that Phenyl-1-Pyridin-2yl-Ethanone-Based iron chelators, PPYeT and PPYaT, inhibit HIV-1 replication by inducing expression of IkB? and p21.
We used a custom designed array of 42 known restriction factors to analyze the effect of PPYeT on regulation of these restriction factors of HIV-1. Further we knocked down the identified factors (p21 or CH25H) and then carried out HIV-1 infection in presence of PPYeT to confirm the role of these factors in PPYeT mediated HIV-1 inhibition. Finally, humanized mice were infected with HIV-1 and PPYeT was administered intraperitoneally to confirm in-vivo role of PPYeT in HIV-1 restriction.
Significant upregulation of p21 and CH25H was observed in PPYeT treated THP-1 cells. Knockdown of p21 or CH25H reversed HIV-1 inhibition by PPYeT, further suggesting that these factors mediated HIV-1 inhibition by PPYeT. Treatment with non-related protein phosphatase-1 targeting compound 1E7-03 inhibited HIV-1 in p21 or CH25H knockdown cells. PPYeT treatment significantly suppressed HIV-1 replication in PBMC and THP-1 derived macrophages infected with HIV-1(IIIB) and HIV-1(B-al). In vivo, intraperitoneal administration of PPYeT reduced HIV-1 replication as reflected by reduced levels of HIV-1 TAR RNA, env mRNA and gag mRNA in humanized PBMC-reconstituted NSG mice.
Iron chelator PPYeT inhibits HIV-1 replication by inducing levels of p21 and CH25H. It showed efficacy in HIV-1 infected humanized mice, suggesting its utility in future antiretroviral therapy.